负载大麻二酚的骆驼乳外泌体在耐多柔比星三阴性乳腺癌异种移植中的体内药效学和药代动力学评估

IF 4 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Mounika Aare, Sandeep Chary Padakanti, Mandip Singh
{"title":"负载大麻二酚的骆驼乳外泌体在耐多柔比星三阴性乳腺癌异种移植中的体内药效学和药代动力学评估","authors":"Mounika Aare,&nbsp;Sandeep Chary Padakanti,&nbsp;Mandip Singh","doi":"10.1208/s12249-025-03201-9","DOIUrl":null,"url":null,"abstract":"<div><p>Cannabidiol (CBD) suffers from poor aqueous solubility and extensive first-pass metabolism, which significantly limits its oral bioavailability. In our earlier work, we developed camel milk-derived exosomes (CMDE) as nanocarriers to enhance CBD bioavailability, confirmed through in vivo pharmacokinetic evaluations. In this study, we further characterized the formulation by performing an in silico physiologically based pharmacokinetic (PBPK) simulation using GastroPlus™, integrating in vitro dissolution data. The simulation demonstrated that CBD absorption improved markedly with exosomal encapsulation, achieving 97.8% compared to 13.1% for free CBD. Additionally, CBD-exosomes produced an 8.66-fold increase in maximum plasma concentration (Cmax) and a 7.15-fold increase in the area under the curve (AUC), with predominant uptake observed in the duodenum and jejunum. These computational findings closely mirrored our in vivo results, providing mechanistic insights into the enhanced oral absorption of CBD via exosomal encapsulation. Furthermore, in vitro cytotoxicity studies revealed that combining CBD-CMDE with Paclitaxel (PTX) produced synergistic effects, enabling a two-fold reduction in the required PTX dose. In MDA-MB-231 DOX RT xenograft models, the combination of CBD-CMDE and PTX reduced tumor burden by 2.5-fold relative to controls. Western blot analyses indicated significant downregulation of PI3K/AKT/mTOR pathway regulators, along with modulation of immune markers, suggesting an immune-activating component. Whole-body imaging further confirmed the in vivo targetability of CMDE. This study represents the first application of PBPK modeling, based on in vitro dissolution data, to assess the pharmacokinetics of CBD-exosomes. By integrating computational and preclinical evidence, our findings underscore the potential of exosome-based oral drug delivery systems in enhancing therapeutic efficacy.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 7","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1208/s12249-025-03201-9.pdf","citationCount":"0","resultStr":"{\"title\":\"In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts\",\"authors\":\"Mounika Aare,&nbsp;Sandeep Chary Padakanti,&nbsp;Mandip Singh\",\"doi\":\"10.1208/s12249-025-03201-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cannabidiol (CBD) suffers from poor aqueous solubility and extensive first-pass metabolism, which significantly limits its oral bioavailability. In our earlier work, we developed camel milk-derived exosomes (CMDE) as nanocarriers to enhance CBD bioavailability, confirmed through in vivo pharmacokinetic evaluations. In this study, we further characterized the formulation by performing an in silico physiologically based pharmacokinetic (PBPK) simulation using GastroPlus™, integrating in vitro dissolution data. The simulation demonstrated that CBD absorption improved markedly with exosomal encapsulation, achieving 97.8% compared to 13.1% for free CBD. Additionally, CBD-exosomes produced an 8.66-fold increase in maximum plasma concentration (Cmax) and a 7.15-fold increase in the area under the curve (AUC), with predominant uptake observed in the duodenum and jejunum. These computational findings closely mirrored our in vivo results, providing mechanistic insights into the enhanced oral absorption of CBD via exosomal encapsulation. Furthermore, in vitro cytotoxicity studies revealed that combining CBD-CMDE with Paclitaxel (PTX) produced synergistic effects, enabling a two-fold reduction in the required PTX dose. In MDA-MB-231 DOX RT xenograft models, the combination of CBD-CMDE and PTX reduced tumor burden by 2.5-fold relative to controls. Western blot analyses indicated significant downregulation of PI3K/AKT/mTOR pathway regulators, along with modulation of immune markers, suggesting an immune-activating component. Whole-body imaging further confirmed the in vivo targetability of CMDE. This study represents the first application of PBPK modeling, based on in vitro dissolution data, to assess the pharmacokinetics of CBD-exosomes. By integrating computational and preclinical evidence, our findings underscore the potential of exosome-based oral drug delivery systems in enhancing therapeutic efficacy.</p><h3>Graphical Abstract</h3>\\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":6925,\"journal\":{\"name\":\"AAPS PharmSciTech\",\"volume\":\"26 7\",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1208/s12249-025-03201-9.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AAPS PharmSciTech\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1208/s12249-025-03201-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS PharmSciTech","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1208/s12249-025-03201-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

大麻二酚(CBD)水溶性差,首过代谢广泛,这极大地限制了其口服生物利用度。在我们早期的工作中,我们开发了骆驼奶衍生外泌体(CMDE)作为纳米载体来提高CBD的生物利用度,并通过体内药代动力学评估得到了证实。在这项研究中,我们通过使用GastroPlus™进行基于生理的药代动力学(PBPK)模拟,整合体外溶出度数据,进一步表征了该配方。模拟表明,外泌体包封显著改善了CBD的吸收,达到97.8%,而游离CBD的吸收率为13.1%。此外,cbd外泌体使最大血浆浓度(Cmax)增加8.66倍,曲线下面积(AUC)增加7.15倍,主要摄取于十二指肠和空肠。这些计算结果密切反映了我们的体内结果,为通过外泌体包封增强CBD口服吸收提供了机制见解。此外,体外细胞毒性研究表明,将CBD-CMDE与紫杉醇(PTX)联合使用可产生协同效应,使所需的PTX剂量减少两倍。在MDA-MB-231 DOX RT异种移植模型中,与对照组相比,CBD-CMDE和PTX联合使用可将肿瘤负荷降低2.5倍。Western blot分析显示,PI3K/AKT/mTOR通路调节因子显著下调,同时免疫标记物也受到调节,提示存在免疫激活成分。全身成像进一步证实了CMDE的体内靶向性。该研究首次应用PBPK模型,基于体外溶出度数据来评估cbd外泌体的药代动力学。通过综合计算和临床前证据,我们的发现强调了基于外泌体的口服给药系统在提高治疗效果方面的潜力。图形抽象
本文章由计算机程序翻译,如有差异,请以英文原文为准。
In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts

Cannabidiol (CBD) suffers from poor aqueous solubility and extensive first-pass metabolism, which significantly limits its oral bioavailability. In our earlier work, we developed camel milk-derived exosomes (CMDE) as nanocarriers to enhance CBD bioavailability, confirmed through in vivo pharmacokinetic evaluations. In this study, we further characterized the formulation by performing an in silico physiologically based pharmacokinetic (PBPK) simulation using GastroPlus™, integrating in vitro dissolution data. The simulation demonstrated that CBD absorption improved markedly with exosomal encapsulation, achieving 97.8% compared to 13.1% for free CBD. Additionally, CBD-exosomes produced an 8.66-fold increase in maximum plasma concentration (Cmax) and a 7.15-fold increase in the area under the curve (AUC), with predominant uptake observed in the duodenum and jejunum. These computational findings closely mirrored our in vivo results, providing mechanistic insights into the enhanced oral absorption of CBD via exosomal encapsulation. Furthermore, in vitro cytotoxicity studies revealed that combining CBD-CMDE with Paclitaxel (PTX) produced synergistic effects, enabling a two-fold reduction in the required PTX dose. In MDA-MB-231 DOX RT xenograft models, the combination of CBD-CMDE and PTX reduced tumor burden by 2.5-fold relative to controls. Western blot analyses indicated significant downregulation of PI3K/AKT/mTOR pathway regulators, along with modulation of immune markers, suggesting an immune-activating component. Whole-body imaging further confirmed the in vivo targetability of CMDE. This study represents the first application of PBPK modeling, based on in vitro dissolution data, to assess the pharmacokinetics of CBD-exosomes. By integrating computational and preclinical evidence, our findings underscore the potential of exosome-based oral drug delivery systems in enhancing therapeutic efficacy.

Graphical Abstract

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AAPS PharmSciTech
AAPS PharmSciTech 医学-药学
CiteScore
6.80
自引率
3.00%
发文量
264
审稿时长
2.4 months
期刊介绍: AAPS PharmSciTech is a peer-reviewed, online-only journal committed to serving those pharmaceutical scientists and engineers interested in the research, development, and evaluation of pharmaceutical dosage forms and delivery systems, including drugs derived from biotechnology and the manufacturing science pertaining to the commercialization of such dosage forms. Because of its electronic nature, AAPS PharmSciTech aspires to utilize evolving electronic technology to enable faster and diverse mechanisms of information delivery to its readership. Submission of uninvited expert reviews and research articles are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信